Clinical Trial

HEALEY ALS Platform Trial - Regimen I NUZ-001

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with ALS.
Protocol Amendment History 2 changes
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-07-21
notable Enrollment increased: 160 -> 240 participants 2026-07-17
Trial Details
NCT Number NCT07410806
Lead Sponsor Merit E. Cudkowicz, MD
Collaborators: Neurizon Therapeutics Limited
Conditions Amyotrophic Lateral Sclerosis (ALS)
Enrollment 240 participants
Start Date 2026-02-25
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-20